Precision for Medicine, the first global biomarker-driven clinical research and development organization, today announced that it has acquired Baseline Controls, a Raleigh, North Carolina-based company that provides dedicated engineers with specialized expertise in project feasibility, execution planning, and baseline performance management. Baseline Control's expertise will become part of Project Farma, Precision for Medicine's existing biomanufacturing strategy and execution group, expanding the scope of its manufacturing solutions for life science companies and driving greater speed and efficiency in bringing new drugs to market.

"Our partnerships are with the most innovative organizations, utilizing the most advanced, cutting-edge technologies and providing us with unparalleled experience in manufacturing small molecule, biologics and next-generation medicines," said John Khoury, Executive Vice President at Project Farma. "This acquisition allows us to vastly expand our capabilities and deliver efficient and strategic solutions that drive the path forward for manufacturing complex treatments while ensuring reliable and consistent drug supply chains."

The addition of Baseline Controls expands Precision for Medicine's capabilities in manufacturing and provides faster, more cost-efficient solutions for bringing complex treatments to market. The combination of Project Farma's consultative leadership in the manufacturing of life-changing medicines and Baseline Control's expertise in project controls and project management will greatly enhance the company's ability to address technical operations challenges for life sciences companies, with a unique focus on organizations operating in the rapidly growing area of cell and gene therapy.

Adam Barlow, Principal and President of Baseline Controls, said, "We see this is an excellent fit for Baseline Controls, bringing us one step closer to achieving our vision of creating a project controls center of excellence for our clients. I look forward to joining the Project Farma leadership team as we combine our unique offerings to support our life sciences clients, from ideation to commercialization."

"Unraveling the complexity of manufacturing next-gen biologics is critical to the shared mission of accelerating patient access to new therapies," said Chad Clark, President of Precision for Medicine. "The addition of Baseline Controls significantly expands our ability to plan, build and maintain technical operations for our clients, from early-stage and established biotech to large biopharma companies."

 

Source:prnewswire.com

Report Abuse